Drug interactions
Irinotecan liposomal + Rolapitant
Severity: Moderate
Irinotecan liposomal and Rolapitant: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rolapitant inhibits BCRP, and the active metabolite of irinotecan (SN-38) is a BCRP substrate. Exposure to SN-38 could therefore rise, potentially worsening neutropenia and diarrhea. The clinical significance is not well characterised.
What this interaction means in plain words
Irinotecan liposomal and Rolapitant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Rolapitant inhibition of BCRP efflux may increase systemic exposure to SN-38.
What to do
Monitor blood counts and for severe diarrhea during chemotherapy cycles when rolapitant is used. Manage toxicity per irinotecan dose-modification guidance.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Irinotecan liposomal and Rolapitant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Rolapitant
- Pimozide + Rolapitant Contraindicated
- Rolapitant + Thioridazine Contraindicated
- Atomoxetine + Rolapitant Major
- Deutetrabenazine + Rolapitant Major
- Eliglustat + Rolapitant Major
- Flecainide + Rolapitant Major
Frequently asked questions
Can I take Irinotecan liposomal with Rolapitant?
MediHelp rates the interaction as moderate. Irinotecan liposomal and Rolapitant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Rolapitant inhibits BCRP, and the active metabolite of irinotecan (SN-38) is a BCRP substrate. Exposure to SN-38 could therefore rise, potentially worsening neutropenia and diarrhea. The clinical significance is not well characterised.
How serious is the interaction between Irinotecan liposomal and Rolapitant?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and for severe diarrhea during chemotherapy cycles when rolapitant is used. Manage toxicity per irinotecan dose-modification guidance.
What other medicines interact with Rolapitant?
MediHelp also lists interactions of Rolapitant with, for example, Pimozide, Thioridazine, Atomoxetine. The full list is on the Rolapitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
